First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis.
Xueqiong CaoHongfu CaiNa LiBin ZhengZhiwei ZhengMaobai LiuPublished in: Therapeutic advances in medical oncology (2022)
NI is more cost-effective than NC or chemotherapy alone for treating advanced ESCC with PD-L1 expression ⩾1% in the United States. Chemotherapy alone is the only cost-effective option in China.